Hosted on MSN4h
Vertex processes first ore for early gold RewardVertex Minerals (ASX:VTX) has processed first ore and begun commissioning of the high-grade Reward gold mine, with sales ...
Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...
Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...
Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Hosted on MSN6h
Shares rally as Vertex on track for first gold sales next month: Reward plant commissioning underwayVertex Minerals (ASX:VTX) is on track to sell first gold from its Reward Gold Mine in the Eastern Lachlan Fold Belt of ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback